Saito Norihiko, Hirai Nozomi, Koyahara Yuki, Sato Sho, Hiramoto Yu, Fujita Satoshi, Nakayama Haruo, Hayashi Morito, Iwabuchi Satoshi
Neurosurgery, Toho University Ohashi Medical Center, Tokyo, JPN.
Cureus. 2024 Feb 20;16(2):e54503. doi: 10.7759/cureus.54503. eCollection 2024 Feb.
Prolactin-secreting pituitary neuroendocrine tumors (PitNETs) are more common in women. Male patients may also have few symptoms and have macroadenomas extending outside the sella turcica. This study aimed to report the results of cabergoline treatment in male patients with prolactin-secreting PitNET. The study included nine male patients aged 26-65 years (median, 46 years) diagnosed with prolactin-secreting PitNETs. The age at onset, prolactin values, tumor size, symptoms, and treatment were assessed. The mean prolactin value at the initial presentation was 2734.6 ng/mL, and the mean maximum tumor diameter was 40.4 mm. Visual field disturbance was the most common symptom (44.4%), followed by headaches (33.3%), asymptomatic symptoms (11.1%), and galactorrhea (11.1%). Eight patients responded to cabergoline treatment with normalization of prolactin levels and tumor shrinkage. One patient did not respond to the cabergoline treatment and required surgical intervention. There were no cases of cerebrospinal fluid leakage. Cabergoline was found to be an effective treatment for male prolactin-secreting PitNETs.
分泌催乳素的垂体神经内分泌肿瘤（PitNETs）在女性中更为常见。男性患者可能症状也较少，且存在向蝶鞍外延伸的大腺瘤。本研究旨在报告卡麦角林治疗男性分泌催乳素的PitNETs的结果。该研究纳入了9名年龄在26 - 65岁（中位数为46岁）的男性患者，他们被诊断为分泌催乳素的PitNETs。对发病年龄、催乳素值、肿瘤大小、症状及治疗情况进行了评估。初次就诊时催乳素的平均水平为2734.6 ng/mL，肿瘤最大直径的平均值为40.4 mm。视野障碍是最常见的症状（44.4%），其次是头痛（33.3%）、无症状（11.1%）和溢乳（11.1%）。8例患者对卡麦角林治疗有反应，催乳素水平恢复正常且肿瘤缩小。1例患者对卡麦角林治疗无反应，需要手术干预。未发生脑脊液漏的病例。发现卡麦角林是治疗男性分泌催乳素的PitNETs的有效方法。
